MRT-2359

What is MRT-2359?

MRT-2359 is an orally bioavailable selective molecular glue degrader that targets GSPT1, promoting its binding to cereblon and inducing GSPT1 degradation. This downregulates L-MYC and N-MYC, disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling. It is studied in MYC-driven tumors including NSCLC, SCLC, neuroendocrine cancer, DLBCL, and breast and prostate cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Small molecule (Molecular glue degrader)

Targets

GSPT1, cereblon (CRBN) (binding partner it blocks), L-MYC (MYCL) (secondary target), N-MYC (MYCN) (secondary target)

Mechanism

Degrader of GSPT1

Pathways

MYC-driven protein translation, protein translation

Therapy area

Oncology

Developer

Monte Rosa Therapeutics, Inc (GLUE)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

M2R4A9NKZ8

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DLBCLHigh Grade Neuroendocrine CancerHR-positive, HER2-negative Breast CancerL-MYC and N-MYC Amplified Solid TumorsNSCLCNSCLC With High or Low L-MYC or N-MYC ExpressionProstate CancerSCLC

More from Monte Rosa Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05546268
• ClinicalTrials.gov NCT05546268
• ClinicalTrials.gov NCT05546268

Updated Oct 3, 2026. Something wrong or missing? Report it on the GLUE page.